Zhijie Wang
Clinical trials sponsored by Zhijie Wang, explained in plain language.
-
New Two-Pronged attack on deadly lung cancer subtype
Disease control Not yet recruitingThis study is testing a new combination treatment for a fast-growing type of lung cancer called SMARCA4-deficient NSCLC. It will give patients a new dual-action immunotherapy drug (QL1706) along with standard platinum-based chemotherapy as their first treatment. The main goals ar…
Phase: PHASE2 • Sponsor: Zhijie Wang • Aim: Disease control
Last updated Apr 04, 2026 07:37 UTC
-
New drug combo targets 'Undruggable' lung cancer
Disease control Not yet recruitingThis study is testing a new combination treatment for people with a specific, hard-to-treat form of advanced lung cancer (SMARCA4-deficient). All participants will receive an oral pill called anlotinib alongside standard platinum-based chemotherapy. The main goals are to see if t…
Phase: PHASE2 • Sponsor: Zhijie Wang • Aim: Disease control
Last updated Apr 01, 2026 14:40 UTC